Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.
The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S. Food and Drug Administration for use in adults with refractory Mycobacterium avium complex (MAC) lung disease. ARIKAYCE is designed to deliver high concentrations of antibiotic directly to the lungs, and Insmed has pursued both commercial uptake and further regulatory and clinical work to explore additional indications and geographic approvals.
Beyond its marketed product, Insmed maintains a clinical-stage pipeline focused on pulmonary and other rare disease indications, leveraging formulation science and targeted delivery approaches. The company conducts clinical trials, regulatory interactions, and commercial activities aimed at expanding patient access to its therapies. Insmed also engages in partnerships and business development efforts to support international registrations and distribution.
Insmed presents itself as a specialty biopharma organization combining R&D, regulatory, and commercial capabilities to serve patients with high unmet medical need. Its operations encompass clinical development, regulatory strategy, manufacturing partnerships for specialized formulations, and patient support programs intended to facilitate access and adherence for those living with chronic and complex conditions.
AI Generated. May Contain Errors.
